Novartis Reports Positive Results for Avian Flu Vaccine

Novartis (NYSE: NVS  )  today announced positive clinical trial results for its vaccine for the H7N9 avian flu, marking the first major step made by a large pharmaceutical company in treating the virus. There have been 135 confirmed H7N9 cases of and 45 deaths since the virus was identified in March.

The Centers for Disease Control and Prevention currently recommends two drugs for the treatment of H7N9 -- Tamiflu, developed by Gilead Sciences (NASDAQ: GILD  ) and marketed by Roche (NASDAQOTH: RHHBY  ) , and Relenza, created by Biota Pharmaceuticals (NASDAQ: AVIR  ) and marketed by GlaxoSmithKline (NYSE: GSK  ) .

Orally administered Tamiflu is widely recommended as the first treatment. Relenza, which is inhaled or administered intravenously, is recommended for patients who have trouble tolerating oral Tamiflu due to gastrointestinal problems. However, the overall efficacy of Tamiflu and Relenza in the treatment of H7N9 is still unknown, since both treatments are designed to treat a wide variety of flu strains, rather than a single one.

Novartis makes impressive progress
According to Novartis' interim report, the H7N9 vaccine protected 85% of tested patients who received two doses of the vaccine combined with MF59, Novartis' own immunologic adjuvant. Adjuvants are added to flu vaccines to stimulate the body's immune system response and help the vaccine take effect. The difference that MF59 made was impressive -- without the adjuvant, Novartis' H7N9 vaccine only protected 6% of patients after two doses.

Novartis' H7N9 vaccine was manufactured through full-scale cell-culture technology, which uses a mammalian cell line -- a much faster production method than the traditional method of growing flu virus strains in chicken eggs.

After sharing the initial vaccine trial results with the Chinese Centers for Disease Control and Prevention, Novartis started clinical trials on the vaccine in August and began large-scale production in American and German production facilities in October.

Both Sanofi and Novartis have been working with the National Institutes of Health in the United States to develop an effective H7N9 vaccine.

Will progress in H7N9 help Novartis' vaccines business?
Out of Novartis' five business segments -- branded pharmaceuticals, Alcon eye-care products, Sandoz generic pharmaceuticals, consumer health, and vaccines -- its vaccines segment has consistently been the least significant, as seen in the following chart.


Vaccines Revenue

Growth (YOY)

Percentage of Total Revenue

4Q 2012

$628 million



1Q 2013

$327 million



2Q 2013

$411 million



3Q 2013

$594 million



Source: Novartis quarterly reports.

Novartis' vaccines unit notably posted the strongest performance in the second quarter of the year, due to robust demand for seasonal influenza treatments and bulk shipments of pediatric vaccines.

However, Novartis' vaccines business, which includes its diagnostic tools and services, is considerably smaller than its rivals. By comparison, GlaxoSmithKline reported $1.6 billion in revenue from its vaccines unit, which accounted for 15% of its top line.

Yet Novartis' recent progress with the H7N9 vaccine and the proven efficacy of the MF59 adjuvant could substantially increase the weight of the vaccines segment. Moreover, Novartis recently slimmed down the unit, divesting the blood transfusion diagnostics part of the business to Grifols for $1.7 billion.

In addition to these recent developments, Novartis has also considered selling the entire vaccines unit along with the veterinary division of its consumer health business, according to a recent Bloomberg report.

The Foolish takeaway
The positive news regarding Novartis' H7N9 vaccine probably won't be enough of a catalyst to cause shares to rally. However, Novartis has already performed fairly well over the past 12 months and stayed ahead of the overall market.

NVS Chart

Source: YCharts.

Investors should now pay closer attention to the company's often-overlooked vaccines unit -- will it grow bigger to rival larger competitors like GSK and Roche, get broken up and divested further, or sold altogether to generate cash that can be invested in higher-growth businesses, such as generics and consumer health?

A growth stock you should keep an eye on
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 16, 2013, at 2:39 PM, zincfinger wrote:

    Novavax (NVAX) beat NVS to the draw on the H7N9 vaccine:

    1) NVAX begain it's clinical trial months before NVS (primarily due to NVAX's much faster process: From viral sequence to testing in animals in only 3 months and injection into humans in only 4 months.

    2) NVAX's results (published in a letter in NEJM (and article in DEC) were released first. NVS's results appear to be a frantic attempt to not appear to be caught short and were only PRed not published AFAICD.

    3) NVS' vaccine had similar results is some aspects (not all) but requited 3 times the dose

    4) NVAX's final results are due in August 2014, NVS's not until October 2014.

    5) NVAX's vaccine is produced in insect cells, a much lower cost production method than NVS's which are produced in mammalian cells. [[since both vaccines are made from a portion of a viral protein there are no significant differences due to the dirrerent production platforms (glycosylation etc)

    Novartis has been considering selling its vaccine unit:

    "Novartis is also considering selling its over-the-counter medicines unit and the vaccines operation, they said. No final decision on those assets has been made, the people said." (Bloomburg)

    It's hard to interpret their H7N9 vaccine announcement as anything other than an attempt to prop up the value of the vaccine unit pending a possible sale IMHO

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2725945, ~/Articles/ArticleHandler.aspx, 9/29/2016 4:51:48 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 12.84 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:02 PM
NVS $81.22 Up +0.34 +0.42%
Novartis CAPS Rating: ****
AVIR $1.94 Up +0.04 +2.11%
Biota Pharmaceutic… CAPS Rating: ****
GILD $78.97 Down -0.28 -0.35%
Gilead Sciences CAPS Rating: *****
GSK $43.67 Up +0.35 +0.81%
GlaxoSmithKline CAPS Rating: ***
RHHBY $31.57 Up +0.18 +0.57%
Roche Holding Ltd.… CAPS Rating: *****